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Chagas disease (CD), caused by Trypanosoma cruzi,a ﬀects approximately eight million individuals in Latin America and is
emerging in nonendemic areas due to the globalisation of immigration and nonvectorial transmission routes. Although CD
represents an important public health problem, resulting in high morbidity and considerable mortality rates, few investments
have been allocated towards developing novel anti-T. cruzi agents. The available therapy for CD is based on two nitro derivatives
(benznidazole (Bz) and nifurtimox (Nf)) developed more than four decades ago. Both are far from ideal due to substantial
secondary side eﬀects, limited eﬃcacy against diﬀerent parasite isolates, long-term therapy, and their well-known poor activity
in the late chronic phase. These drawbacks justify the urgent need to identify better drugs to treat chagasic patients. Although
several classes of natural and synthetic compounds have been reported to act in vitro and in vivo on T. cruzi, since the introduction
of Bz and Nf, only a few drugs, such as allopurinol and a few sterol inhibitors, have moved to clinical trials. This reﬂects, at least
in part, the absence of well-established universal protocols to screen and compare drug activity. In addition, a large number of
in vitro studies have been conducted using only epimastigotes and trypomastigotes instead of evaluating compounds’ activities
against intracellular amastigotes, which are the reproductive forms in the vertebrate host and are thus an important determinant
in the selection and identiﬁcation of eﬀective compounds for further in vivo analysis. In addition, due to pharmacokinetics and
absorption, distribution, metabolism, and excretion characteristics, several compounds that were promising in vitro have not been
as eﬀective as Nf or Bz in animal models of T. cruzi infection. In the last two decades, our team has collaborated with diﬀerent
medicinalchemistrygroupstodeveloppreclinicalstudiesforCDandinvestigatetheinvitroandinvivoeﬃcacy,toxicity,selectivity,
andparasitetargetsofdiﬀerentclassesofnaturalandsyntheticcompounds.Someoftheseresultswillbebrieﬂypresented,focusing
primarily on diamidines and related compounds and naphthoquinone derivatives that showed the most promising eﬃcacy against
T. cruzi.
1.ChagasDisease andIts Treatment
Chagas disease (CD) is caused by the intracellular obligatory
parasite Trypanosoma cruzi. The life cycle of this parasite
involves haematophagous triatomine insect vectors, diverse
vertebrate mammalian hosts, and diﬀerent developmen-
tal forms. Brieﬂy, after bloodstream trypomastigotes are
ingested by an insect, they are converted to epimastigotes,
which proliferate and diﬀerentiate into metacyclic forms
within the posterior intestine of the triatomine. These
infective forms, released within the faeces and urine, can
invade vertebrate cells and undergo another round of
diﬀerentiation into the intracellular amastigote forms, which
proliferate and then transform back to trypomastigotes, the
form that disseminates the infection. CD is the major cause
of infectious cardiopathy and represents an important public2 Molecular Biology International
health problem; it is broadly dispersed in 18 developing
countries in South and Central America [1]. It aﬀects
approximately eight million people in Latin America, of
whom 30–40% either have or will develop cardiomyopathy,
digestive megasyndromes, or both [2]. CD transmission
occurs primarily via the vector (90%) but may also occur
through blood transfusion and congenital transmission as
well as laboratory accidents [3], organ transplantation [4],
and ingestion of contaminated food and beverages [5].
Recently, CD has become a major concern due to globali-
sation, which results in immigration of infected individuals
to nonendemic regions, thus spreading the disease [6].
Although both vectorial and transfusional transmission have
sharply declined in the past 20 years due to Southern
Cone countries’ policies, several challenges still need to
be overcome, including those related to sustainable public
health initiatives, vector control strategies, and educational
approaches [7, 8]. Thus, because epidemiological and trans-
mission control characteristics of CD may vary according
to each country’s ecological conditions and adopted health
policies, continuous epidemiological survey in conjunction
with eﬃcient and universal therapy of the infected individ-
uals must be performed to maintain and even reduce the
number of new acute cases [9].
CD aﬀects mainly poor, rural and forgotten populations
and has two consecutive clinical phases: the acute phase that
appears shortly after infection, which ranges from ﬂu-like
symptoms to intense myocarditis (in approximately 10% of
infected people), and the chronic symptomatic phase, which
develops in approximately one-third of infected individuals
after an asymptomatic period (indeterminate form) lasting
years or decades [10, 11]. The main clinical manifestations
of the chronic stage include cardiac and/or gastrointestinal
involvement, and the variability in CD outcome has been
related to host response and parasite heterogeneity [12].
Although its pathology is poorly understood, growing
evidence has shown that parasitic persistence within the
target organs associated with an unregulated host immune
response is involved in pathogenesis, disease progression,
and outcome [1, 13, 14].
Since its discovery by Chagas more than a hundred
years ago [15], CD still poses many challenges, including
its peculiar epidemiology, characterised by a variety of risk
factors (diverse vectors and reservoirs and diﬀerent forms
of transmission and parasite isolates present in domiciliar,
peridomiciliar, and sylvatic environments), and the lack
of prophylactic therapies and eﬀective chemotherapeutic
schemes [10, 16, 17].
Nifurtimox ([3-methyl-4-(5 -nitrofurfurylideneamine)
tetrahydro-4H-1,4-tiazine-1,1-dioxide], Nf) and benznida-
zole (N-benzyl-2-nitroimidazole acetamide, Bz) were empir-
icallyintroducedinto the clinical therapy regime forCD over
four decades ago. Neither drug is ideal because they present
variable results depending on the phase of the disease (they
areonlyeﬀectiveintheacuteandrecentchronicphasesofthe
infection), the dose and duration of the treatment, patient
age, and endemic region in addition to showing undesirable
secondary side eﬀects [18, 19]. Additionally, diﬀerences in
the susceptibility and natural resistance of diﬀerent T. cruzi
isolates to both nitroderivatives have also been reported
[20]. It has been suggested that CD must be treated in
all its stages, including acute (acquired or congenital),
chronic reactivated (under immunosuppressive conditions),
indeterminate, and early chronic phases, as determined by
the presence of parasitic DNA using PCR analysis [21].
Additionally, although there is still no criterion of cure
for symptomatic late chronic cases because most treated
individuals show positive serology, recent data suggest the
beneﬁts of Bz therapy for chronic patients through the arrest
of cardiac damage and a decrease in serology titres [22,
23]. These results reinforce a goal for identifying parasitic
targets that is strengthened by the concept that chagasic
cardiomyopathy is related to parasitic persistence within
the target organs along with an unbalanced host immune
response, which could be useful for a new CD therapy [24].
Since the introduction of Bz and Nf, only allopurinol
and a few azoles, such as itraconazole, ﬂuconazole, and
ketoconazole, have moved to clinical trials [25–27]. In fact,
drug development eﬀorts for CD are almost exclusively
in preclinical research, although phase II studies for the
antifungal drug posaconazole and a prodrug of ravuconazole
are being planned [28]. In addition, clinical data have
demonstrated a positive eﬀect of posaconazole in the therapy
of a chronic chagasic patient with systemic lupus erythe-
matosus [29]. However, the high costs of posaconazole may
impair its use in CD.
The gap between preclinical studies and clinical trials
may be associated with the small amount of investments by
pharmaceutical industries due to the low monetary return
and to the previous mistaken concept that during the later
stages of CD, parasitism is absent [30]. In addition, the lack
of standardised protocols and the use of epimastigotes for
drugscreeningmayrepresentsigniﬁcantimpairmentsforthe
discovery of novel anti-T. cruzi candidates [31]. Based on
current knowledge regarding parasite and host physiology,
a promising trypanocidal drug would include the following
characteristics: (i) high activity against the parasitic forms
present in mammalian hosts (intracellular amastigotes and
bloodstream trypomastigotes), (ii) high activity against
diverse T. cruzi strains for use in diﬀerent endemic regions,
(iii) eﬃcacy against both acute and chronic infections,
(iv) oral bioavailability in few doses, (v) low toxicity and
improved safety with low potential for genotoxicity and
teratogenicity given the potential use in children and women
of reproductive age, (vi) low cost and high stability for
a long shelf-life in tropical temperatures, (vii) high levels
of tissue accumulation and long terminal half-lives, (viii)
low risk for cardiotoxicity because the heart is the primary
organ aﬀected in chagasic patients, and (ix) low risk for
interactions with hepatic cytochrome P450s to avoid drug-
drug interactions because many patients use antiarrhythmic
drugs and anticoagulants [28, 32].
2.ParasiteTargets andLeadCompounds
for New Drugs
Advances in proteomics, biochemistry, and in understanding
the biological aspects of T. cruzi infection have allowed forMolecular Biology International 3
the development of new approaches to identify parasite-
speciﬁc targets and, thus, the design of novel potential drugs
[33, 34]. It has been proposed that a rational therapy for T.
cruzi should be directed against diﬀerent parasitic metabolic
targets, including ergosterol biosynthesis, trypanothione
metabolism, cysteine protease, pyrophosphate metabolism,
protein or purine synthesis, and DNA [21, 28, 35–37]. The
combination of diﬀerent drugs with the aim of achieving
higher eﬃciency and lower toxicity is also an interesting
therapeutic strategy [38]. Recent studies have demonstrated
the successful synergism of posaconazole with amiodarone,
an antiarrhythmic drug, against T. cruzi in vitro and in vivo
[39]. Another relevant approachis the aetiological therapy of
CD using carrier molecules, such as ruthenium complexes,
that bind 14a-demethylase inhibitors [40] or benznidazole
[41], improving both solubility and parasite speciﬁcity [28].
A recent study has shown the successful use of ruthenium
complexes to deliver nitric oxide to T. cruzi-infected cells
[42].
Proteomic approaches have been extensively applied for
the evaluation of the expression, structure, and function of
proteins on a large-scale, including their physiological role,
expression regulation, and validity of genome annotations
[43]. In trypanosomatids, the control of gene expression is
particularly important because all protein-encoding genes
are organised in large polycistronic transcription units,
producing the RNA that will be processed by trans-splicing.
Furthermore, the modulation of protein expression and,
consequently, its function is directly related to posttransla-
tional modiﬁcations in these protozoa [44, 45]. Proteomic
studies have been performed to evaluate the mechanisms of
T. cruzi resistance/susceptibility to drugs [44–46].
In the present review, we summarise in vitro and in vivo
results on the eﬃcacy, toxicity, selectivity, and cellular targets
ofaromaticdiamidinesandnaphthoquinonederivatives,two
groups of compounds with promising eﬃcacy against T.
cruzi. In this framework, morphological techniques, such as
light (confocal and ﬂuorescence) and electron (transmission
and scanning) microscopy, have been employed. Other
cellular (ﬂow cytometry), biochemical (respirometry and
ﬂuorimetry), and proteomic (bidimensional electrophoresis
andmassspectrometry)approacheshavealsobeenemployed
to identify speciﬁc targets in the parasite.
2.1. Aromatic Diamidines and DNA Damages. Diamidines,
such as pentamidine, propamidine, and diminazene acetu-
rate, have been successfully used in human and veterinary
medicine, and they are the ﬁrst class of drug extensively
employed for early-stage human African trypanosomiasis
and for cutaneous leishmaniasis caused by Leishmania
guyanensis [47–49]. Their major drawbacks are poor oral
bioavailability and severe side eﬀects. To overcome these
issues, new dicationic analogues and prodrugs have been
synthesised by diﬀerent medicinal chemistry groups and
widely assayed in vitro and in vivo [50]. One of the
most promising compounds is an orally eﬀective prodrug
of furamidine (DB75) named DB289, which has been in
phase III clinical trials for African trypanosomiasis [51].
Unfortunately, recent results at an extended dosage led to
the withdrawal of DB289 from human trials due to toxicity
issues.
Despitethestrongactivityofthesedicationiccompounds
against African trypanosomes, few have been assayed as
anti-T. cruzi candidates [50]. Our team has recently been
working on the potential eﬀect of diamidines and congeners
against this parasite using both in vitro and in vivo models
to compare analogues with diﬀerent structures, cationic
centres, and eﬀective motifs [19]. Our data have clearly
shown the promising activity of some of these compounds,
which displayed high therapeutic windows [52–56].
Although DB75 and its N-phenyl-substituted analogue
(DB569) display equivalent DNA-binding properties, DB569
exhibited higher in vitro activity against diﬀerent strains and
stages of T. cruzi,w i t hI C 50 values in the low micromolar
range [57]. Due to the characteristic ﬂuorescence of these
diamidines, their localisation in DNA-enriched organelles
was determined due to strong labelling of the kDNA
[58]. Flow cytometry and transmission electron microscopy
(TEM) analysis also demonstrated that DB75 and DB569
disturb parasite mitochondria and nuclei, leading to mor-
phological characteristics of programmed cell death, such as
higher levels of apoptotic-like parasites observed after the
treatment with DB569 [57, 59]. These ﬁndings stimulated
further in vivo analysis with this analogue, which showed a
reduction in the number of parasites and CD8+ Tc e l l si n
hearttissuesandreversionofelectrocardiogram(ECG)alter-
ationsinacutelyT.cruzi-infectedmice,leadingtoanincrease
in the survival rates [60]. The ECG protection provided
by DB569 was also found during the chronic infection of
experimental animals, suggesting that the reversion observed
in treated animals may be associated with the reduction
in cardiac CD8+ lymphocyte inﬁltration and parasitism,
ultimately contributing to their survival [59, 60].
A diarylthiophene diamidine (DB1362) was evaluated
against amastigotes and bloodstream trypomastigotes of T.
cruzi and showed good eﬃcacy in vitro at submicromolar
concentrations, inducing low host cytotoxicity. This diami-
dine presented a dose-dependent trypanocidal eﬀect after
incubation in the presence of plasma constituents (mouse
blood), exhibiting IC50 values similar to those found in the
absenceofblood,pointingtoitspotentialprophylacticappli-
cation in blood banks. TEM and ﬂow cytometry have shown
that in bloodstream parasites the most important alterations
were in kinetoplast organisation and mitochondrial mem-
branepotential[54].InanacuteT.cruziexperimentalmouse
model, treatment with two doses of 25mg/kg DB1362 (at the
onset and at the parasitaemia peak) led to a 40% decrease
in the circulating trypomastigotes and cardiac parasitism
(similar levels to Bz) and protected against ECG alterations,
leading to a 100% survival rate [54].
Studies on the biological and ultrastructural eﬀect
and subcellular localisation of six novel diamidines in T.
cruzi conﬁrmed their low toxicity towards mammalian
cells (LC50 > 96μM) and demonstrated that small linear
molecules (DB1627, DB1646, and DB1670) were not eﬀec-
tive. However, the other three diamidines (DB1645, DB1582,
and DB1651) were active, with IC50 values between 0.15 and
13.3μM against bloodstream and intracellular amastigotes
[61].4 Molecular Biology International
Several potential transporters of diamidines have been
described in other parasites, such as African trypanosomes,
Leishmania species and Plasmodium falciparum [62–64].
However, the mechanism of diamidine uptake in T. cruzi
is unknown and requires further investigation. The intrin-
sic ﬂuorescence of some of these compounds allows for
monitoring their localisation, as previously reported in
studies with African trypanosomes [50, 65, 66]. Some of
these diamidines, like DB1582 and DB1651, were localised
in parasitic nuclei and kDNA (with higher intensity in
kDNA) and within punctate non-DNA-containing cytoplas-
mic organelles usually localised in the anterior portion of
trypomastigotes and near the nuclei and kinetoplasts in
amastigotes, which are possibly acidocalcisomes, as previ-
ouslydescribedforT. brucei [65].Aspreviouslysuggestedfor
African trypanosomes, the localisation of these compounds
within these acidic organelles could play a role in their
mechanism of action and/or act as storage sites [65, 66], but
additional studies are needed to clarify this matter. Batista et
al. [61] demonstrated that these diamidines caused striking
alterations in the mitochondria and kinetoplasts of T. cruzi,
and some of them also induced disorganisation of micro-
tubules, with the appearance of multiple axoneme structures
in trypomastigotes [52, 61]. No major alterations have been
reported in either subpellicular or ﬂagellar microtubules
of T. cruzi treated with drugs that target microtubules,
such as taxol, colchicines, and vinblastine, possibly due
to the high content of acetylated tubulin and/or poly-
glutamylation of tubulin in these parasites [67]. Because
these structures are more resistant to microtubule disrupters
in trypanosomatids compared to mammalian cells, they may
representinterestingtargetsfordrugdevelopmentandjustify
further investigations.
Although the exact mechanism of action of diamidines
on T. cruzi and other trypanosomatids has not been clearly
demonstrated, it is likely that multiple modes of action may
be responsible and that compound uptake represents a fun-
damental step in their action and selectivity [50, 68]. One of
the long-hypothesised mechanisms of diamidines is related
to their selective binding to sequences rich in adenosine and
thymine (AT) of kDNA minicircles, leading to kinetoplast
destructionandparasitedeath[58,69].BecausethekDNAof
trypanosomatids contains high numbers of AT-binding sites
in thousands of repeated minicircles, it is possible that these
structures represent potential speciﬁc targets for diamidines
[50]. However, although these compounds are excellent
minor groove DNA-binders, this interaction itself cannot
fully explain their biological activity. Recent reports have
suggested that their association with DNA could represent
an initial step followed by topological changes leading to
molecular instability and destruction and/or modiﬁcation
of DNA-protein interactions, leading to replication errors,
DNA degradation, and parasite death [70]. TEM studies
have shown that the organisation of mitochondria and
kinetoplasts in T. cruzi is highly altered by several diamidines
and related compounds, such as arylimidamides (AIAs),
at concentrations that do not aﬀect mammalian host cells
[19, 51, 58]. AIAs, previously known as reversed amidines,
have extraordinary activity against both Leishmania [71–73]
and T. cruzi [52, 53, 55, 56, 74]. They diﬀer from other
furan analogues because the amidine is bound to the central




through interference with the mitochondrial membrane
potential [53, 54]. In vitro screening of novel diamidines
against T. cruzi has shown that these compounds localise to
a higher extent within the kinetoplast than in the nucleus,
and no correlation was found between trypanocidal activity
and higher kDNA accumulation [75, 76], as previously
reported in T. brucei [65]. Other targets for diamidines that
also have been proposed include the inhibition of tyrosyl-
DNA phosphodiesterase, topoisomerases, protein kinase A,
proteases, and polymerases [51, 77, 78].
To better understand the mechanism of action of these
aromatic compounds, a study of the possible correlation
between kDNA-binding properties of 13 amidines with their
trypanocidal eﬃcacy against T. cruzi was performed. Four
diamidines (DB75, DB569, DB1345, and DB829), eight
arylimidamides (DB766, DB749, DB889, DB709, DB613A,
DB1831, DB1852, and DB2002), and one guanylhydrazone
(DB1080)wereassayedusingthermaldenaturation(Tm)and
circular dichroism (CD) studies using both whole T. cruzi
puriﬁed kDNA and a conserved synthetic parasitic sequence
corresponding to the biological activity of each compound
[79]. The ﬁndings suggest that the strong interaction of
amidines with kDNA may not be suﬃcient to generate and
trigger their trypanocidal activity, and other mechanisms of
action may be involved and/or associated.
AIAs have potent in vitro dose-dependent activity against
T. cruzi, showing superior trypanocidal activity compared to
diguanidino cationic groups and other classical diamidines
[52, 56]. Recently, a monoamidine, an arylimidamide, and
a guanylhydrazone were evaluated, and the data showed
that all compounds exerted, at low micromolar doses, a
trypanocidal eﬀect upon both intracellular and bloodstream
parasites [74]. However, the potency and selectivity of
DB613A, an AIA, towards intracellular parasites (with a
selective index >126) corroborated previous results that
demonstrated the high promising trypanocidal activity of
these compounds.
In vitro and in vivo studies conducted with a novel
AIA, DB766, showed its strong trypanocidal activity and
excellent selectivity for intracellular amastigotes and try-
pomastigotes (Y strain), the two relevant parasite forms
present in mammalian hosts, exhibiting IC50 values of 25
and 60nM, respectively [61]. DB766 also exerted striking
eﬀects on a wide panel of diﬀerent parasite strains, including
those naturally resistant to Nf and Bz, displaying higher
activity in vitro than Bz and gentian violet, which are
important requirements for identifying a potential anti-T.
cruzi agent. It is also important to point that DB766 was
active against parasite isolates that circulate in peridomiciliar
and sylvatic ecotopes from two diﬀerent regions in Brazil: (i)
the northeast (Jaguaribe Valley, Cear´ a state) that represents
an important area for CD surveillance, where high rates of
natural triatomine infection are observed (mostly T. cruziMolecular Biology International 5
type I lineage) and vectorial control still requires eﬀort to
avoid new cases of human transmission, and (ii) the Amazon
region that presents an important new epidemiologic chal-
lenge due to the increasing reports of human acute cases,
mainly by oral contamination as well as by wild triatomine
vectorial transmission [61]. Next, as no major acute toxicity
was noted with uninfected mice, this AIA was moved to
models of acute and chronic experimental T. cruzi infection.
DB766 eﬀectively reduced the parasite load in blood and
cardiac tissue and presented similar eﬃcacy to Bz in mouse
models of acute and chronic T. cruzi infection (using Y
and Colombiana strains, which are considered modered and
highly resistant to Bz), using few oral and intraperitoneal
doses up to 100mg/kg/day given after the establishment of
parasite infection. As T. cruzi is an obligatory intracellular
parasite and reservoirs of amastigotes can be found in quite
distinct organs and tissues, the ability of AIAs (including
DB766) to traverse host cell membranes possibly by passive
diﬀusion and or transporters associated with their extensive
tissue binding in liver, spleen, and heart [80] makes this class
of compounds very attractive for CD treatment. In fact, the
pharmacokinetic properties of DB766 are especially relevant
since the poor activity of the nitroheterocyclic compounds
during the chronic stages of CD may be related to short
half-lives and limited tissue penetration of Bz and Nf. The
eﬃcacy of DB766 upon several strains in vitro and in vivo
is a very important ﬁnding since this parasite comprises
numerous clonal populations with distinct characteristics
such as diﬀerent sensitivity to Nf and Bz, diverse biological
parameters and enzymatic diversity, and strain heterogeneity
may also be related to the diﬀerent clinical manifestations
and outcomes in CD. Thus, the broad spectrum of DB766
activity is a desirable characteristic of a novel compound for
the treatment of this neglected illness. In acute experimental
models of T. cruzi infection, DB766 ameliorated heart
alterations, reduced hepatic and heart lesions induced by
the infection, and provided 90–100% protection against
mortality. DB766 also presented high in vivo eﬃcacy when
given orally at 100mg/kg/day, showing similar eﬀect to the
Bz-treated group [61]. Interestingly, the oral administration
of DB766 (at 100mg/kg/day) leads to reduced circulating
and cardiac parasitism besides protecting against mortality
without causing major side eﬀects. These results suggest
that although not being a prodrug, suﬃcient quantities of
DB766 were absorbed from the mouse gastrointestinal tract,
eﬀectively delivering this AIA across the gut mucosa, similar
tothatreportedfortheADprodrugDB289.Thebulkofthese
results demonstrate the promising trypanocidal eﬃcacy of
DB766, suggesting that AIA may represent a new lead
candidate for CD treatment. Interestingly, DB766 produced
a clear dose-dependent decrease in parasitaemia in the liver,
spleen and bone marrow in two experimental models of
L. donovani infection [80]. Additionally, pharmacokinetics,
mutagenicity, and toxicity studies revealed that this AIA did
not exhibit mutagenicity (AMES test), displayed low acute
toxicity, had moderate oral bioavailability, was distributed
to diﬀerent tissues (such as the liver and spleen), presented
large areas of distribution, and showed an elimination half-
life ranging from one to two days in mice [80].
Six novel aromatic amidinic compounds were tested in
vitro to determine activity against the infective and intra-
cellular stages of T. cruzi and evaluate their selectivity and
toxicity towards primary cultures of cardiomyocytes [56].
Thedatademonstratedthatallofthearomaticamidineswere
active against T. cruzi in vitro and that the arylimidamide
DB1470 was the most eﬀective compound, presenting IC50
values at submicromolar levels and a good selectivity index
and maintaining signiﬁcant trypanocidal activity at 4◦Ci n
the presence of blood constituents [56]. Interestingly, AIAs,
such as DB1470 and DB766, exhibited potent trypanocidal
activity against T. cruzi in the presence of blood constituents
[52, 55]. This characteristic is highly desirable for new
potential trypanocidal agents for use in blood banks in
endemicareas.Unfortunately,althoughtransfusionalcontrol
has led to a decline in the number of new blood bank-
related infections, it is not universally performed. The only
trypanocidal agent available for chemical prophylaxis of
blood in areas of high endemicity is gentian violet, which is a
toxic cationic dye that gives a purple colour to the blood and
stains the skin and mucosa of the recipients [10, 81]. These
limitations encourage the search for new compounds that
could be used in blood bank prophylaxis; thus, AIAs such as
DB766 represent promising agents for further evaluation for
thispurpose[55].Insummary,theeﬃcacyofdiamidinesand
congeners, like AIAs, against T. cruzi requires further studies
to help establish a valuable scheme of therapy for CD.
2.2. Naphthoquinone Derivatives and Mitochondrial Dysfunc-
tion. Naphthoquinones are compounds present in diﬀerent
families of plants that serve as vital links in the electron
transport chains in the metabolic pathway and participate
in multiple biological oxidative processes [82, 83]. They are
considered privileged structures in medicinal chemistry due
to their biological activities and structural properties [84].
The redox cycling of quinones may be initiated by either a
one- or two-electron reduction. The one electron reduction
leads to the formation of semiquinones, unstable interme-
diates that react rapidly with molecular oxygen, generating
free radicals. All of these highly reactive oxygen species
(ROS) may react directly with DNA or other cellular macro-
molecules, such as lipids and proteins, leading to cell damage
[85]. This reaction results in shunting electrons toward
oxygen, an ineﬀective pathway for reduction equivalents
otherwise used for cytochrome P450 reductase-dependent
reactions [86–89]. Another alternative is reduction by two
electrons, leading to the formation of hydroquinone, medi-
ated by DT-diphorase [90, 91]. This enzyme reduces toxic,
reactive, and unstable quinones, bypassing the creation of
toxicintermediates(e.g.,asemiquinoneradical),andsparing
the cell from ROS formation. Whether the two-electron
reductionofaquinoneleadstodetoxiﬁcationortoactivation
of oxidative stress depends upon the rate of autoxidation
of the formed hydroquinone [86]. If this rate is low under
physiological conditions, conjugation may occur before
oxidation. As a consequence, the two-electron reduction
will lead to detoxiﬁcation, and an increase in the DT-
diphorase activity in tissues would be expected to decrease
the toxicity of the quinone. If, however, the hydroquinone6 Molecular Biology International
is rapidly oxidised, only a minor fraction may be conjugated
beforeoxidationoccurs,andhydroquinoneformationwould
constitute an activation reaction. As a result, enhanced tissue
levels of NQO1 would be expected to increase the toxicity of
the quinone [92]. Quinones are oxidants and electrophiles,
and the relative contribution of these properties to both
their toxic and therapeutic activities is inﬂuenced by their
chemical structure [93]. Two major mechanisms of quinone
cytotoxicity have been proposed: stimulation of oxidative
stress and alkylation of cellular nucleophiles, which are
the mechanisms of action of encompass a large range of
biomolecules [94]. Cellular damage can also occur through
the alkylation of crucial proteins and nucleic acids.
In addition to their widespread presence in nature,
the great interest in the study and mechanisms of action
of compounds with a quinoidal structure is due to their
multiple roles in organisms. Several quinonoids isolated
from traditional medicinal plants are being investigated for
their anticancer properties [95]. The antiprotozoal activities
of naphthoquinones have been reported, and several of them
have been identiﬁed as possible leads for drug development
[96–98].
Lapachol is easily isolated from the heartwood of trees
of the Bignoniaceae family abundant in tropical rainforests,
while both α-lapachone and β-lapachone are present only in
small amounts. In Brazil, more than 46 types of such woods,
popularly known by the name “ipes” (Tabebuia sp.), have
been described. In folk medicine, especially among Indian
populations, plants containing naphthoquinones have been
employed for the treatment of diﬀerent diseases, such as
cancer [99, 100]. The inner bark of Tabebuia avellanedae,
commonlyknownas“paud’arco”(lapacho,taheebo),isused
as an analgesic, an anti-inﬂammatory, an antineoplastic, and
a diuretic by the local people in the northeastern regions of
Brazil [101].
Previous reports have shown that against T. cruzi epi-
mastigotes, β-lapachone increases the generation of reactive
oxygen species through formation of the semiquinone
radical, leading to lipid peroxidation and inhibition of
nucleic acid and protein synthesis [102–106]. T. cruzi is
known to be deﬁcient in reactive oxygen and nitrogen
species detoxiﬁcation and for being especially sensitive to
oxidative stress conditions [107]. Its single mitochondrion,
containing a branched electron transport chain and a
specialisedkDNAregion[77],isanextraordinarydrugtarget
[33]. The ultrastructural injuries observed in β-lapachone-
treated epimastigotes [108] together with the increase in the
generation of hydrogen peroxide clearly demonstrates the
mitochondrial susceptibility of T. cruzi to naphthoquinones.
Unfortunately, no trypanocidal eﬀect was observed in sus-
pensions containing foetal calf serum or rabbit haemoglobin
solution, suggesting that β-lapachone could be inactivated
by either reduction in the presence of oxyhaemoglobin or
interaction with serum proteins [109].
Due to the easy access to natural sources of quinones
from Brazilian ﬂora and the synthetic mechanisms devel-
oped by the group of Dr. Pinto (NPPN/UFRJ) exploring
the electrophilicity of 1,2-quinoidal carbonyls [110–113],
naphthoquinones have been used as starting points for
medicinal chemistry studies. Since the 90s, our group has
been studying the anti-T. cruzi activity of this class of
chemicals [114]. An initial screening was performed on
60 derivatives obtained through the reaction of several
naphthoquinones with common reagents from heterocyclic
chemistry, leading to 14 oxazolic, 30 imidazolic, and 10
other related heterocyclic compounds [115–119]. Compar-
ing the activity of the original naphthoquinones and their
derivatives, we concluded that minor structural features
involved with an increase in lipophilicity, such as the
furane moiety, the presence of a methoxyl group, and an
aliphatic side chain, led to an increase in the eﬀect on
T. cruzi. It is possible that a lipophilic character allows
better penetration of the compound through the plasma
membrane of the parasite. The activity of the synthesised
compounds on T. cruzi showed no uniform behaviour and
was in some cases higher, lower, or similar to the activity
of the original naphthoquinones from which they were
obtained. For the naphthooxazoles assayed, there was no
correlation between biological activity and the type of the
mono-oxygenated ring (pyrane versus furane). As shown for
naphthoquinones, a lipophilic characteristic, introduced by
this appendage, and the presence of a methoxyl or a phenyl
group increased the trypanocidal activity. A characteristic
of the synthesised naphthoimidazoles was that most of
them had aromatic groups containing electron-releasing
or electron-withdrawing groups attached to the imidazole
ring, and the most active compounds against T. cruzi were
obtained from β-lapachone (see Section 2.3)[ 115, 119].
Another group of naphthoquinone derivatives was
also synthesised and assayed on trypomastigote forms,
including β-lapachone- and nor-β-lapachone-based 1,2,3-
triazoles and 3-arylamino-nor-β-lapachones [120, 121].
1,2,3-Triazoles are an important class of heterocyclic
compounds due to their wide range of biological activities.
The strategy of molecular hybridisation linking them to
naphthoquinones resulted in compounds endowed with
redox properties and a trypanocidal proﬁle. The 1,2,3-
triazole derivatives of nor-β-lapachone were more active
than the original quinone, and the apolar phenyl-substituted
derivative (2,2-dimethyl-3-(4-phenyl-1,2,3-triazol-1-yl)-
2,3-dihydro-naphtho[1,2-b]furan-4,5-dione) was the most
active compound (IC50/24h = 17.3 ± 2.0μM) [120]. Such
activity could be due to its higher lipophilic character,
which allows better penetration through the parasite’s
plasma membrane. In addition, the key intermediate
azides used for the synthesis of both the β-lapachone and
nor-β-lapachone series of 1,2,3-triazoles displayed higher
activity than Bz (IC50/24h = 103.6 ± 0.6μM). In the case of
nor-β-lapachones-3-arylamino-substituted compounds, the
insertion of chlorine, bromine, nitro, and methoxy groups
into the arylamino ring intensiﬁed the trypanocidal activity.
Using nor-lapachol as a starting point, substituted
ortho-naphthofuranquinones, a nonsubstituted para-
naphthofuranquinone, an oxyrane and an azide were
prepared. Using α-lapachone as a base, a new nonsubstituted
para-naphthofuranquinone was prepared. The most active
compounds were three ortho-naphthofuranquinones with
trypanocidal activity higher than that of Bz [122]. In anotherMolecular Biology International 7
set of experiments, three new naphthofuranquinones were
synthesised and assayed on T. cruzi. Two of them were
obtained by the addition of iodine to C-allyl-lawsone (2-
hydroxy-3-allyl-naphthoquinone) followed by cyclisation,
generating a furan ring; the third was obtained through
an acid-catalysed reaction by dissolution of the original
quinone in sulphuric acid. These compounds were active on
bloodstream trypomastigote and epimastigote forms with
IC50 values between 165–640 and 2.5–25μM, respectively
[123].Thetreatmentofinfectedmurinemacrophagescaused
a dose-dependent decrease in the percentage of infection
with low toxicity to host mammalian cells (over 100μM),
with IC50/24–96h values for intracellular amastigotes
between 1.2 and 3.5μM[ 124]. An ultrastructural analysis
of treated epimastigotes and trypomastigotes indicated
ap o t e n te ﬀect of the three naphthofuranquinones on
parasitic mitochondria, which appeared drastically swollen
and with a washed-out matrix proﬁle. Fluorescence-
activated cell sorting analysis of rhodamine-123-stained
T. cruzi showed that these naphthofuranquinones caused
a potent dose-dependent collapse of the mitochondrial
membrane potential (ΔΨm), especially in epimastigote
forms. Such a collapse represented a 30–60% decrease in the
parasitic ΔΨm. These compounds also speciﬁcally decreased
mitochondrial complex I-III activities parallel to a reduction
in succinate-induced oxygen consumption between 64–
75% in epimastigotes and 72–92% in trypomastigotes.
Mitochondrial hydrogen peroxide formation was also
increased 1.3–4.5-fold in epimastigotes after treatment
with naphthofuranquinones. Our results indicated that the
trypanocidal action of these quinones was associated with
mitochondrial dysfunction, leading to increased reactive
oxygen species generation and parasitic death [124]. The
easy synthetic route of these compounds in the laboratory
opens the possibility of large-scale production with high
yields for assays in experimental mouse models.
2.3. Naphthoimidazoles and Putative Targets. Among the dif-
ferentclassesofnaphthoquinonederivativesscreenedagainst
T. cruzi (see Section 2.2) , the most active derivatives against
bloodstream trypomastigotes were three naphthoimidazoles
derived from β-lapachone with the aromatic moieties phenyl
(N1),3-indolyl(N2),andmethyl-p-phenyl(N3),whichwere
selected for further studies [84, 85]. They were also active
against intracellular amastigotes and epimastigotes (Table 1)
and showed toxicity to the host cell in concentrations greater
than 100μM. The most susceptible form of the parasite was
the intracellular amastigotes, with an IC50/24h between 6.5
and 9.0μM[ 125, 126]. The highest activity against blood-
stream forms was observed for N2, with IC50/24h values
of 12.3 ± 1.2 and 61.6 ± 3.6μM for 0% and 100% blood,
respectively.Inepimastigotes,N3wasthemosteﬀective,with
IC50/24 h values of 30.7 ± 3.6 μM. All three compounds
also blocked the cell cycle (up to 96% inhibition of DNA
duplication), inhibited succinate cytochrome c reductase
(16–42%) and metacyclogenesis (IC50/96h values between
0.35–0.66μM)andinducedextensivemorphologicaldamage
to the mitochondria, Golgi complex and reservosomes.
In treated trypomastigotes, an altered kinetoplast network,
mitochondrial swelling, plasma membrane blebbing and
DNA fragmentation were found [125, 126]. DNA fragmen-
tation was also evaluated using total DNA electrophoresis
and ﬂow cytometry techniques and showed a maximum
of 75% TUNEL+ trypomastigotes after treatment with the
naphthoimidazoles.
An investigation into their mode of action led to the
characterisationofmitochondria,reservosomes,andDNAas
theirmaintargetsandstimulated furtherstudiesaboutdeath
pathways. Ultrastructural analysis revealed both autophagic
(autophagosomes) and apoptotic-like (membrane blebbing)
phenotypes. In epimastigotes and trypomastigotes, the
naphthoimidazoles induced the formation of concentric
membranes, autophagosomes with a loss of matrix electron
density, and endoplasmic reticulum proﬁles surrounding
diﬀerentstructures[127].Apoptosis-likefeatures,suchasthe
release of mitochondrial cytochrome c to the cytosol, has
also been detected in N3-treated parasites. Flow cytometry
analysis showed a small increase in phosphatidylserine
exposure in N2-treated trypomastigotes and a large increase
in the percentage of necrosis caused by N1 and N2. These
death phenotypes were not detected in treated epimastig-
otes. A strong increase in the labelling of monodansyl
cadaverine (a well-known autophagic marker) was observed
up to 45 and 71% in treated trypomastigotes and epi-
mastigotes, respectively. The inhibition of the trypanocidal
action of the three naphthoimidazoles by wortmannin or
3-methyladenine together with the overexpression of ATG3,
ATG4, ATG7, and ATG8 genes in treated epimastigotes and
the ultrastructural evidence pointed to autophagy as the
predominant phenotype induced by these compounds [127,
128].
To assess the mechanism of action of the naphthoimida-
zoles N1, N2, and N3, treated epimastigotes were submitted
to two-dimensional gel electrophoresis (2-DE) and mass
spectrometry to monitor changes in the protein patterns
of diﬀerent important pathways in T. cruzi. Results showed
that 9 of the 30 proteins altered were mitochondrial,
reinforcing previous morphological and biochemical studies
that showed this organelle as the main target of these
drugs [125, 126]. Treatment with the compounds led to
an upregulation of three proteins: heat-shock protein 85,
enolase 1 and trypanothione synthetase (Table 2). The over-
modulation of the trypanothione pathway strongly suggests
that increased scavenging is necessary due to the increased
thiol content in treated parasites, as previously described for
trypanosomatids [129].
Thedownregulationof26proteinswasobserved:7inN1,
14 in N2, and 15 in N3. Table 2 summarises all modulated
proteins after treatment. A strong decrease (20–80%) in
protein levels was detected after treatment with the three
naphthoimidazoles. Energy metabolism is an important
target of these compounds. The expression of enzymes,
such as enolase, pyruvate dehydrogenase, and cytochrome c
oxidase, were altered in treated epimastigotes. Interference
with ATP generation occurred in diﬀerent stages of the
pathway, including glycolysis, the citric acid cycle, and the
mitochondrial electron transport chain. The main structural
targetofnaphthoimidazoleswasmicrotubules.Aremarkable8 Molecular Biology International
Table 1: IC50 values/1d (μM) for the eﬀect of N1, N2, and N3 against T. cruzi a.
Trypomastigotes Epimastigotes Amastigotes
0% blood 100% blood Extracellularb Intracellularc
N1 35.8 ± 1.2d 62.1 ± 3.0 82.8 ± 7.4 13.4 ± 1.1 9.0 ± 2.9
N2 12.3 ± 1.2 61.6 ± 3.6 36.0 ± 1.9 12.4 ± 1.9 6.5 ± 1.0
N3 28.2 ± 0.9 68.3 ± 7.3 30.7 ± 3.6 9.7 ± 0.2 7.2 ± 0.2
aReferences [123, 124].
bTissue-cultured derived amastigotes.
cNumber of amastigotes/100 peritoneal macrophages.
dMean ± SD of at least 3 independent experiments.
Table 2: Modulated proteins in naphthoimidazoles-treated epimastigotesa.
Protein description Expression status Treatment
Trypanothione synthetase upregulated N1, N2, N3
Mitochondrial heat shock downregulated N1
Heat shock protein 60 downregulated N2
Elogation factor 1-α downregulated N1
Enolase 1 upregulated N3
Glutamamyl carboxypeptidase downregulated N1
Heat shock protein 85 upregulated/downregulated N1, N2, N3
Tyrosine aminotransferase downregulated N3
Cytochrome C oxidase subunit IV downregulated N2
Activated PKC receptor downregulated N3
Hypothetical protein downregulated N2
β-tubulin downregulated N1, N2
Pyruvate dehydrogenase E1 β subunit downregulated N3
Sterol 24-C-methyltransferases downregulated N2, N3
Elongation factor 1-β downregulated N2
Proteosome α 7 subunit downregulated N1
Peroxiredoxin downregulated N2
Hypothetical protein downregulated N1
IgE-dependent histamine-releasing factor downregulated N3
Elongation factor 2 downregulated N2
Dehydrogenase downregulated N3
Cystathionine β-synthase 6 downregulated N2
α-tubulin downregulated N3
aReference [128].
decrease in the α-a n dβ-tubulin content was detected in
epimastigotes treated with the three compounds. Interest-
ingly, previous ultrastructural data showed no damage to
subpellicular and ﬂagellar conformations after treatment
[125, 126]. ELISA showed a decrease in tyrosinated tubulin
content, suggesting interference with intracellular vesicle
traﬃc and/or mitotic spindle formation, data reinforced
by the blockage of mitosis in naphthoimidazole-treated
epimastigotes [126, 130]. Amino acid metabolism was one
of the most important targets of the naphthoimidazoles. The
levels of tyrosine aminotransferase, elongation factors and
diﬀerent heat-shock proteins were aﬀected by N1, N2, and
N3, leading to a decrease in the amino acid synthesis and,
consequently, an imbalance in proteins important for cell
survival. N2 and N3 also arrested the latter steps of sterol
biosynthesis through the downregulation of sterol 24-C-
methyltransferase (Table 2). The partial impairment of this
pathway could lead to alterations in the lipid composition,
with a loss of membrane ﬂuidity. Proteomic and ultrastruc-
tural data showed no evidence of necrosis or apoptosis-like
cell death in treated parasites [127, 130]. A further detailed
study on metabolic interactions iscrucialtofurtherelucidate
the mechanisms through which naphthoimidazoles act.
3. Concluding Remarks
Despite the drawbacks found during the therapy of chagasic
patients with Bz and Nf, in the last decades, only a few
compounds have moved to clinical trials, possibly due to
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near future” [131]. Thus, the recent implementation of high-
throughput compound screening against T. cruzi will allow
for the rapid evaluation of several thousands of compounds
per month against intracellular amastigotes, which represent
an important tool that may yield the identiﬁcation of novel
promising compounds that can move to clinical trials [28].
However, these promising trypanocidal candidates will
needmorecompletepharmacologicalandsafetytestanalyses
to be considered for clinical trials. However, consistent care
must be provided through the adoption of a biopsychoso-
cial model, considering patient therapy in the context of
biological, psychological, and social factors, and economic
diﬃculties, which can compromise quality of life [132, 133].
Finally, another important limitation related to moving
new compounds towards clinical trials is the absence of
feasible markers to monitor the progression of the chronic
disease and aﬀordable, eﬃcient, and accessible diagnostic
tests. Thus, the development of new drugs for most parasitic
diseases requires a multidisciplinary approach involving
diverseresearchareas,suchasmolecularandcellularbiology,
chemistry and biochemistry, pharmacology, and toxicology,
to provide new insights related to the development and
discovery of more selective compounds that could be used
for Chagas disease therapy.
As concluded by Abad-Franch et al. [8],i m p r o v e ds p e -
ciﬁc chemotherapy, including more practical formulations
(e.g., paediatric) or combinations of existing drugs, and a
better understanding of pathogenesis as well as the relative
contribution of the parasite and host genetic makeup are
clearly needed. New strategies for drug design have been
improved by the recent results in T. cruzi biochemistry,
allowing for better elucidation of the eﬀects of trypanocidal
agents.
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